Mersana Therapeutics to Present at Upcoming Investor Conferences
Mersana Therapeutics (NASDAQ:MRSN), a clinical-stage biopharmaceutical company, announced management presentations at three investor conferences. The Baird 2021 Global Healthcare Conference will take place on September 14, 2021, at 8:30 a.m. ET, followed by the Morgan Stanley 19th Annual Global Healthcare Conference on September 15, 2021, at 1:15 p.m. ET. Lastly, the 2021 Cantor Virtual Global Healthcare Conference is set for September 28, 2021, at 4:00 p.m. ET. A live webcast will be accessible on Mersana's website, with an archived replay available for 90 days.
- None.
- None.
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at three upcoming investor conferences. Details are as follows:
| Baird 2021 Global Healthcare Conference | |
| Format: | Fireside Chat |
| Date/Time: | Tuesday, September 14, 2021, at 8:30 a.m. ET |
| Morgan Stanley 19th Annual Global Healthcare Conference | |
| Format: | Fireside Chat |
| Date/Time: | Wednesday, September 15, 2021, at 1:15 p.m. ET |
| 2021 Cantor Virtual Global Healthcare Conference | |
| Format: | Presentation |
| Date/Time: | Tuesday, September 28, 2021, at 4:00 p.m. ET |
A live webcast of these events will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 90 days following the event.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registration strategy in patients with platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase 1 umbrella study in combination with other ovarian cancer therapies. UpRi is also being studied in the expansion portion of a Phase 1 proof-of-concept clinical study. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines. The Company routinely posts information that may be useful to investors on the “Investors and Media” section of our website at www.mersana.com.
Contact:
Investor & Media Contact
Sarah Carmody
617-844-8577
scarmody@mersana.com
FAQ
What investor conferences will Mersana Therapeutics present at in September 2021?
What is the schedule for Mersana's presentations at the healthcare conferences?
Where can I watch the presentations by Mersana Therapeutics?
What is the focus of Mersana Therapeutics' pipeline?
What is the ticker symbol for Mersana Therapeutics?
